Wald Patrick, Liu X Shawn, Pettit Cory, Dillhoff Mary, Manilchuk Andrei, Schmidt Carl, Wuthrick Evan, Chen Wei, Williams Terence M
The Ohio State University Medical Center, Arthur G. James Comprehensive Cancer Center and Richard J. Solove Research Institute, Columbus, OH 43210.
Oncotarget. 2017 Aug 16;8(42):73345-73361. doi: 10.18632/oncotarget.20277. eCollection 2017 Sep 22.
Clinical and pathologic markers of prognosis and patterns of failure help guide clinicians in selecting patients for adjuvant therapy after surgical resection for pancreatic adenocarcinoma (PDAC). Recent studies have reported the prognostic utility of microRNA profiling in numerous malignancies. Here, we review and summarize the current literature regarding associations between microRNA expression and overall survival in PDAC patients.
We conducted a systematic search in the PubMed database to identify all primary research studies reporting prognostic associations between tumor and/or serum microRNA expression and overall survival in PDAC patients. Eligible articles were reviewed by the authors and relevant findings are summarized below.
We found 53 publications that fit our search criteria. In total, 23 up-regulated and 49 down-regulated miRNAs have been associated with worse overall survival. MiR-21 is the most commonly reported miRNA, appearing in 19 publications, all of which report aberrant over-expression and association with shorter survival in PDAC. Other miRNAs that appear in multiple publications include miR-10b, -21, -34a, -155, -196a, -198, -200c, -203, -210, -218, -222, and -328. We summarize the preclinical and clinical data implicating these miRNAs in various molecular signaling pathways and cellular functions.
There is growing evidence that miRNA expression profiles have the potential to provide tumor-specific prognostic information to assist clinicians in more appropriately selecting patients for adjuvant therapy. These molecules are often aberrantly expressed and exhibit oncogenic and/or tumor suppressor functions in PDAC. Additional efforts to develop prognostic and predictive molecular signatures, and further elucidate miRNA mechanisms of action, are warranted.
预后的临床和病理标志物以及失败模式有助于指导临床医生为胰腺腺癌（PDAC）手术切除后的患者选择辅助治疗方案。最近的研究报道了微小RNA谱在众多恶性肿瘤中的预后效用。在此，我们回顾并总结了关于PDAC患者微小RNA表达与总生存期之间关联的当前文献。
我们在PubMed数据库中进行了系统检索，以识别所有报告肿瘤和/或血清微小RNA表达与PDAC患者总生存期之间预后关联的原发性研究。符合条件的文章由作者进行了审阅，相关研究结果总结如下。
我们发现53篇符合我们检索标准的出版物。总共有23种上调的和49种下调的微小RNA与较差的总生存期相关。MiR-21是最常被报道的微小RNA，出现在19篇出版物中，所有这些出版物均报道其在PDAC中异常过度表达并与较短生存期相关。其他出现在多篇出版物中的微小RNA包括miR-10b、-21、-34a、-155、-196a、-198、-200c、-203、-210、-218、-222和-328。我们总结了涉及这些微小RNA在各种分子信号通路和细胞功能中的临床前和临床数据。
越来越多的证据表明，微小RNA表达谱有可能提供肿瘤特异性的预后信息，以帮助临床医生更恰当地为患者选择辅助治疗。这些分子在PDAC中常常异常表达，并表现出致癌和/或肿瘤抑制功能。有必要进一步努力开发预后和预测性分子特征，并进一步阐明微小RNA的作用机制。
